Does the media refer more to PRME or BEAM?

In the previous week, Beam Therapeutics had 6 more articles in the media than Prime Medicine. MarketBeat recorded 10 mentions for Beam Therapeutics and 4 mentions for Prime Medicine. Beam Therapeutics' average media sentiment score of 1.06 beat Prime Medicine's score of 0.81 indicating that Beam Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prime Medicine 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Beam Therapeutics 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to MLYS or PRME?

In the previous week, Mineralys Therapeutics had 4 more articles in the media than Prime Medicine. MarketBeat recorded 8 mentions for Mineralys Therapeutics and 4 mentions for Prime Medicine. Mineralys Therapeutics' average media sentiment score of 1.00 beat Prime Medicine's score of 0.81 indicating that Mineralys Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mineralys Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Prime Medicine 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is PHVS or PRME more profitable?

Pharvaris has a net margin of 0.00% compared to Prime Medicine's net margin of -4,917.55%. Pharvaris' return on equity of -67.56% beat Prime Medicine's return on equity. Company Net Margins Return on Equity Return on Assets Pharvaris N/A -67.56% -61.13% Prime Medicine -4,917.55% -188.82% -60.97%

Does the media refer more to PHVS or PRME?

In the previous week, Pharvaris and Pharvaris both had 4 articles in the media. Pharvaris' average media sentiment score of 1.54 beat Prime Medicine's score of 0.81 indicating that Pharvaris is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pharvaris 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Prime Medicine 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer PRME or NUVB?

In the previous week, Nuvation Bio had 8 more articles in the media than Prime Medicine. MarketBeat recorded 12 mentions for Nuvation Bio and 4 mentions for Prime Medicine. Nuvation Bio's average media sentiment score of 0.88 beat Prime Medicine's score of 0.81 indicating that Nuvation Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prime Medicine 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nuvation Bio 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer MESO or PRME?

Prime Medicine has a consensus price target of $7.53, suggesting a potential upside of 157.92%. Given Prime Medicine's stronger consensus rating and higher possible upside, analysts clearly believe Prime Medicine is more favorable than Mesoblast. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mesoblast 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 Prime Medicine 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.88

Which has preferable valuation & earnings, MESO or PRME?

Mesoblast has higher revenue and earnings than Prime Medicine. Mesoblast is trading at a lower price-to-earnings ratio than Prime Medicine, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Mesoblast $17.20M 107.00 -$102.14M -$0.28 N/A Prime Medicine $4.63M 113.91 -$201.14M -$1.23 N/A

Does the media favor MESO or PRME?

In the previous week, Prime Medicine had 1 more articles in the media than Mesoblast. MarketBeat recorded 4 mentions for Prime Medicine and 3 mentions for Mesoblast. Prime Medicine's average media sentiment score of 0.81 beat Mesoblast's score of 0.00 indicating that Prime Medicine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mesoblast 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Prime Medicine 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Prime Medicine (PRME) Competitors

$2.92 0.00 (0.00%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$2.94 +0.02 (+0.68%)

As of 07/31/2026 07:34 PM Eastern

Compare

PRME vs. BEAM, MLYS, PHVS, NUVB, and MESO

Should you buy Prime Medicine stock or one of its competitors? MarketBeat compares Prime Medicine with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Prime Medicine include Beam Therapeutics (BEAM), Mineralys Therapeutics (MLYS), Pharvaris (PHVS), Nuvation Bio (NUVB), and Mesoblast (MESO).

How does Prime Medicine compare to Beam Therapeutics?

Prime Medicine (NASDAQ:PRME) and Beam Therapeutics (NASDAQ:BEAM) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, institutional ownership, dividends, analyst recommendations, valuation and risk.

In the previous week, Beam Therapeutics had 6 more articles in the media than Prime Medicine. MarketBeat recorded 10 mentions for Beam Therapeutics and 4 mentions for Prime Medicine. Beam Therapeutics' average media sentiment score of 1.06 beat Prime Medicine's score of 0.81 indicating that Beam Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prime Medicine	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Beam Therapeutics	7 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Prime Medicine presently has a consensus price target of $7.53, indicating a potential upside of 157.92%. Beam Therapeutics has a consensus price target of $46.85, indicating a potential upside of 83.57%. Given Prime Medicine's stronger consensus rating and higher possible upside, equities analysts plainly believe Prime Medicine is more favorable than Beam Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prime Medicine	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Beam Therapeutics	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.64

70.4% of Prime Medicine shares are owned by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are owned by institutional investors. 16.0% of Prime Medicine shares are owned by company insiders. Comparatively, 3.8% of Beam Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Beam Therapeutics has higher revenue and earnings than Prime Medicine. Beam Therapeutics is trading at a lower price-to-earnings ratio than Prime Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prime Medicine	$4.63M	113.91	-$201.14M	-$1.23	N/A
Beam Therapeutics	$164.01M	16.01	-$79.99M	-$0.68	N/A

Prime Medicine has a beta of 2.31, suggesting that its share price is 131% more volatile than the broader market. Comparatively, Beam Therapeutics has a beta of 2.18, suggesting that its share price is 118% more volatile than the broader market.

Beam Therapeutics has a net margin of -39.66% compared to Prime Medicine's net margin of -4,917.55%. Beam Therapeutics' return on equity of -29.00% beat Prime Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prime Medicine	-4,917.55%	-188.82%	-60.97%
Beam Therapeutics	-39.66%	-29.00%	-22.61%

Summary

Beam Therapeutics beats Prime Medicine on 10 of the 17 factors compared between the two stocks.

How does Prime Medicine compare to Mineralys Therapeutics?

Mineralys Therapeutics (NASDAQ:MLYS) and Prime Medicine (NASDAQ:PRME) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, risk and profitability.

In the previous week, Mineralys Therapeutics had 4 more articles in the media than Prime Medicine. MarketBeat recorded 8 mentions for Mineralys Therapeutics and 4 mentions for Prime Medicine. Mineralys Therapeutics' average media sentiment score of 1.00 beat Prime Medicine's score of 0.81 indicating that Mineralys Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mineralys Therapeutics	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Prime Medicine	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

84.5% of Mineralys Therapeutics shares are held by institutional investors. Comparatively, 70.4% of Prime Medicine shares are held by institutional investors. 18.9% of Mineralys Therapeutics shares are held by company insiders. Comparatively, 16.0% of Prime Medicine shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Mineralys Therapeutics has a beta of 0.66, meaning that its stock price is 34% less volatile than the broader market. Comparatively, Prime Medicine has a beta of 2.31, meaning that its stock price is 131% more volatile than the broader market.

Mineralys Therapeutics has a net margin of 0.00% compared to Prime Medicine's net margin of -4,917.55%. Mineralys Therapeutics' return on equity of -27.92% beat Prime Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mineralys Therapeutics	N/A	-27.92%	-26.98%
Prime Medicine	-4,917.55%	-188.82%	-60.97%

Mineralys Therapeutics has higher earnings, but lower revenue than Prime Medicine. Mineralys Therapeutics is trading at a lower price-to-earnings ratio than Prime Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mineralys Therapeutics	N/A	N/A	-$154.65M	-$2.05	N/A
Prime Medicine	$4.63M	113.91	-$201.14M	-$1.23	N/A

Mineralys Therapeutics presently has a consensus target price of $49.33, suggesting a potential upside of 93.31%. Prime Medicine has a consensus target price of $7.53, suggesting a potential upside of 157.92%. Given Prime Medicine's stronger consensus rating and higher possible upside, analysts plainly believe Prime Medicine is more favorable than Mineralys Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mineralys Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Prime Medicine	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Summary

Mineralys Therapeutics beats Prime Medicine on 8 of the 15 factors compared between the two stocks.

How does Prime Medicine compare to Pharvaris?

Pharvaris (NASDAQ:PHVS) and Prime Medicine (NASDAQ:PRME) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, media sentiment, valuation, dividends, analyst recommendations, earnings, profitability and institutional ownership.

Pharvaris has a net margin of 0.00% compared to Prime Medicine's net margin of -4,917.55%. Pharvaris' return on equity of -67.56% beat Prime Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pharvaris	N/A	-67.56%	-61.13%
Prime Medicine	-4,917.55%	-188.82%	-60.97%

Pharvaris presently has a consensus target price of $50.08, indicating a potential upside of 53.54%. Prime Medicine has a consensus target price of $7.53, indicating a potential upside of 157.92%. Given Prime Medicine's stronger consensus rating and higher possible upside, analysts clearly believe Prime Medicine is more favorable than Pharvaris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharvaris	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.79
Prime Medicine	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

70.4% of Prime Medicine shares are held by institutional investors. 16.0% of Prime Medicine shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Pharvaris and Pharvaris both had 4 articles in the media. Pharvaris' average media sentiment score of 1.54 beat Prime Medicine's score of 0.81 indicating that Pharvaris is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pharvaris	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Prime Medicine	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Pharvaris has higher earnings, but lower revenue than Prime Medicine. Pharvaris is trading at a lower price-to-earnings ratio than Prime Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharvaris	N/A	N/A	-$198.79M	-$3.18	N/A
Prime Medicine	$4.63M	113.91	-$201.14M	-$1.23	N/A

Pharvaris has a beta of -2.31, indicating that its share price is 331% less volatile than the broader market. Comparatively, Prime Medicine has a beta of 2.31, indicating that its share price is 131% more volatile than the broader market.

Summary

Prime Medicine beats Pharvaris on 9 of the 14 factors compared between the two stocks.

How does Prime Medicine compare to Nuvation Bio?

Prime Medicine (NASDAQ:PRME) and Nuvation Bio (NYSE:NUVB) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, profitability, risk, earnings, dividends and valuation.

In the previous week, Nuvation Bio had 8 more articles in the media than Prime Medicine. MarketBeat recorded 12 mentions for Nuvation Bio and 4 mentions for Prime Medicine. Nuvation Bio's average media sentiment score of 0.88 beat Prime Medicine's score of 0.81 indicating that Nuvation Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prime Medicine	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nuvation Bio	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Prime Medicine presently has a consensus price target of $7.53, indicating a potential upside of 157.92%. Nuvation Bio has a consensus price target of $12.88, indicating a potential upside of 103.53%. Given Prime Medicine's stronger consensus rating and higher possible upside, equities analysts clearly believe Prime Medicine is more favorable than Nuvation Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prime Medicine	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Nuvation Bio	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

70.4% of Prime Medicine shares are owned by institutional investors. Comparatively, 61.7% of Nuvation Bio shares are owned by institutional investors. 16.0% of Prime Medicine shares are owned by company insiders. Comparatively, 30.1% of Nuvation Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Prime Medicine has a beta of 2.31, suggesting that its share price is 131% more volatile than the broader market. Comparatively, Nuvation Bio has a beta of 1.52, suggesting that its share price is 52% more volatile than the broader market.

Nuvation Bio has a net margin of -102.06% compared to Prime Medicine's net margin of -4,917.55%. Nuvation Bio's return on equity of -44.10% beat Prime Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prime Medicine	-4,917.55%	-188.82%	-60.97%
Nuvation Bio	-102.06%	-44.10%	-23.80%

Prime Medicine has higher earnings, but lower revenue than Nuvation Bio. Nuvation Bio is trading at a lower price-to-earnings ratio than Prime Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prime Medicine	$4.63M	113.91	-$201.14M	-$1.23	N/A
Nuvation Bio	$62.90M	35.02	-$204.63M	-$0.43	N/A

Summary

Nuvation Bio beats Prime Medicine on 9 of the 17 factors compared between the two stocks.

How does Prime Medicine compare to Mesoblast?

Mesoblast (NASDAQ:MESO) and Prime Medicine (NASDAQ:PRME) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, institutional ownership, earnings, analyst recommendations and profitability.

Mesoblast has a beta of 2.08, suggesting that its stock price is 108% more volatile than the broader market. Comparatively, Prime Medicine has a beta of 2.31, suggesting that its stock price is 131% more volatile than the broader market.

1.4% of Mesoblast shares are held by institutional investors. Comparatively, 70.4% of Prime Medicine shares are held by institutional investors. 18.8% of Mesoblast shares are held by insiders. Comparatively, 16.0% of Prime Medicine shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Mesoblast has a net margin of 0.00% compared to Prime Medicine's net margin of -4,917.55%. Mesoblast's return on equity of 0.00% beat Prime Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mesoblast	N/A	N/A	N/A
Prime Medicine	-4,917.55%	-188.82%	-60.97%

Mesoblast has higher revenue and earnings than Prime Medicine. Mesoblast is trading at a lower price-to-earnings ratio than Prime Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mesoblast	$17.20M	107.00	-$102.14M	-$0.28	N/A
Prime Medicine	$4.63M	113.91	-$201.14M	-$1.23	N/A

In the previous week, Prime Medicine had 1 more articles in the media than Mesoblast. MarketBeat recorded 4 mentions for Prime Medicine and 3 mentions for Mesoblast. Prime Medicine's average media sentiment score of 0.81 beat Mesoblast's score of 0.00 indicating that Prime Medicine is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mesoblast	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Prime Medicine	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Prime Medicine has a consensus price target of $7.53, suggesting a potential upside of 157.92%. Given Prime Medicine's stronger consensus rating and higher possible upside, analysts clearly believe Prime Medicine is more favorable than Mesoblast.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mesoblast	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Prime Medicine	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Summary

Prime Medicine beats Mesoblast on 9 of the 16 factors compared between the two stocks.

Get Prime Medicine News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRME and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PRME vs. The Competition

Export

Metric	Prime Medicine	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$527.41M	$3.54B	$6.86B	$12.42B
Dividend Yield	N/A	3.78%	2.59%	10.03%
P/E Ratio	-2.37	7.38	282.30	24.66
Price / Sales	113.91	1,182.44	561.34	76.65
Price / Cash	N/A	44.80	28.60	46.71
Price / Book	4.36	16.96	10.98	6.07
Net Income	-$201.14M	-$12.56M	$3.49B	$347.99M
7 Day Performance	-2.99%	-1.76%	-0.60%	-0.44%
1 Month Performance	-24.55%	-8.38%	-5.20%	-4.81%
1 Year Performance	N/A	48.40%	62.01%	18.61%

Prime Medicine Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PRME Prime Medicine	3.2231 of 5 stars	$2.92 flat	$7.53 +157.9%	N/A	$527.41M	$4.63M	N/A	N/A	News Coverage
BEAM Beam Therapeutics	2.5419 of 5 stars	$27.29 +3.6%	$46.85 +71.7%	+35.5%	$2.71B	$164.01M	N/A	510	Positive News Upcoming Earnings Gap Up
MLYS Mineralys Therapeutics	3.6782 of 5 stars	$27.52 +3.0%	$49.33 +79.3%	+86.8%	$2.20B	N/A	N/A	28	Positive News
PHVS Pharvaris	3.6306 of 5 stars	$34.45 +2.7%	$50.08 +45.4%	+63.1%	$2.19B	N/A	N/A	30
NUVB Nuvation Bio	3.6448 of 5 stars	$6.41 +2.3%	$12.38 +93.2%	+185.0%	$2.18B	$143.05M	N/A	60	Upcoming Earnings Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PRME) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Prime Medicine (PRME) Competitors

PRME vs. BEAM, MLYS, PHVS, NUVB, and MESO

How does Prime Medicine compare to Beam Therapeutics?

Summary

How does Prime Medicine compare to Mineralys Therapeutics?

Summary

How does Prime Medicine compare to Pharvaris?

Summary

How does Prime Medicine compare to Nuvation Bio?

Summary

How does Prime Medicine compare to Mesoblast?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRME vs. The Competition

Prime Medicine Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Prime Medicine (PRME) Competitors

PRME vs. BEAM, MLYS, PHVS, NUVB, and MESO

How does Prime Medicine compare to Beam Therapeutics?

Does the media refer more to PRME or BEAM?

Do analysts recommend PRME or BEAM?

Do institutionals & insiders have more ownership in PRME or BEAM?

Which has stronger earnings and valuation, PRME or BEAM?

Which has more risk & volatility, PRME or BEAM?

Is PRME or BEAM more profitable?

Summary

How does Prime Medicine compare to Mineralys Therapeutics?

Does the media refer more to MLYS or PRME?

Do insiders and institutionals believe in MLYS or PRME?

Which has more volatility & risk, MLYS or PRME?

Is MLYS or PRME more profitable?

Which has better valuation and earnings, MLYS or PRME?

Do analysts rate MLYS or PRME?

Summary

How does Prime Medicine compare to Pharvaris?

Is PHVS or PRME more profitable?

Do analysts prefer PHVS or PRME?

Do institutionals and insiders have more ownership in PHVS or PRME?

Does the media refer more to PHVS or PRME?

Which has higher valuation & earnings, PHVS or PRME?

Which has more volatility & risk, PHVS or PRME?

Summary

How does Prime Medicine compare to Nuvation Bio?

Does the media prefer PRME or NUVB?

Do analysts prefer PRME or NUVB?

Do insiders and institutionals believe in PRME or NUVB?

Which has more volatility and risk, PRME or NUVB?

Is PRME or NUVB more profitable?

Which has better valuation & earnings, PRME or NUVB?

Summary

How does Prime Medicine compare to Mesoblast?

Which has more volatility & risk, MESO or PRME?

Do institutionals and insiders hold more shares of MESO or PRME?

Is MESO or PRME more profitable?

Which has preferable valuation & earnings, MESO or PRME?

Does the media favor MESO or PRME?

Do analysts prefer MESO or PRME?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRME vs. The Competition

Prime Medicine Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools